Augmentin/Augmentin ES Indications/Uses

Augmentin/Augmentin ES should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Augmentin tablet: Augmentin is indicated for short-term treatment of susceptible bacterial infections: Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis due to Escherichia coli, Proteus mirabilis or Enterococcus faecalis.
Skin and soft tissue infections e.g. boils, abscesses, cellulitis, wound infections.
Bone and joint infections e.g. osteomyelitis.
Dental infections e.g. dentoalveolar abscess.
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Susceptibility to Augmentin will vary with geography and time (see PHARMACOLOGY: Pharmacodynamics under Actions for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
Infections caused by amoxicillin-susceptible organisms are amenable to Augmentin treatment due to its amoxicillin content. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with Augmentin-susceptible β-lactamase producing organisms may therefore be treated with Augmentin.
Augmentin suspension 228 mg/5 mL and 457 mg/5 mL: Augmentin suspension (228 mg/5 mL and 457 mg/5 mL), for twice daily oral dosing, is indicated for short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered.
Upper respiratory tract infections (including ENT) ;e.g. recurrent tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia.
Urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. cellulitis, animal bites.
Dental infections e.g. severe dental abscess with spreading cellulitis.
Susceptibility to Augmentin will vary with geography and time (see PHARMACOLOGY: Pharmacodynamics under Actions for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
Mixed infections caused by amoxicillin-susceptible organisms in conjunction with Augmentin susceptible beta-lactamase-producing organisms may be treated with Augmentin suspension 228 mg/5 mL and 457 mg/5 mL. These infections should not require the addition of another antibiotic resistant to beta-lactamases.
Augmentin ES suspension: Augmentin ES is indicated for the short-term treatment of bacterial infections in paediatric patients at the following sites when caused by Augmentin-susceptible organisms: Upper respiratory tract infections (including ENT) e.g. recurrent or persistent acute otitis media due to Streptococcus pneumoniae (penicillin MIC ≤ 4 µg/ml), Haemophilus influenzae^# and Moraxella catarrhalis^#. Such patients are often characterised by antibiotic exposure for acute otitis media within the preceding 3 months, and are either aged ≤ 2 years or attend daycare; tonsillo-pharyngitis and sinusitis, typically caused by Streptococcus pneumoniae, Haemophilus influenzae^#, Moraxella catarrhalis^# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae^# and Moraxella catarrhalis^#.
Skin and soft tissue infections typically caused by Staphylococcus aureus^# and Streptococcus pyogenes.
Other Augmentin formulations are indicated for short-term treatment of bacterial infections at the following sites when caused by Augmentin-susceptible organisms: Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media typically caused by Streptococcus pneumoniae, Haemophilus influenzae^#, Moraxella catarrhalis^# and Streptococcus pyogenes.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae^# and Moraxella catarrhalis^#.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis, female genital infections typically caused by Enterobacteriaceae^# (mainly Escherichia coli^#), Staphylococcus saprophyticus and Enterococcus species, and gonorrohoea caused by Neisseria gonorrhoeae^#.
Skin and soft tissue infections typically caused by Staphylococcus aureus^#, Streptococcus pyogenes and Bacteroides species^#.
^#Some members of these species of bacteria produce beta-lactamase, rendering them insensitive to amoxicillin alone (see PHARMACOLOGY: Pharmacodynamics: Pharmacodynamic Effects under Actions for further information).
Susceptibility to Augmentin ES will vary with geography and time. Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.